Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:TYME

Tyme Technologies (TYME) Stock Price, News & Analysis

Tyme Technologies logo

About Tyme Technologies Stock (NASDAQ:TYME)

Key Stats

Today's Range
$0.29
$0.32
50-Day Range
$0.24
$0.35
52-Week Range
$0.22
$1.14
Volume
2.68 million shs
Average Volume
1.01 million shs
Market Capitalization
$53.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

Receive TYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

TYME Stock News Headlines

Tim Sykes’ Urgent Trade Alert: “Make this move now”
Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.
Creating a Winter Herb Garden Indoors
See More Headlines

TYME Stock Analysis - Frequently Asked Questions

Tyme Technologies, Inc. (NASDAQ:TYME) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.03.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tyme Technologies investors own include NIO (NIO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Tonix Pharmaceuticals (TNXP), SCYNEXIS (SCYX) and Palantir Technologies (PLTR).

Company Calendar

Last Earnings
11/08/2021
Today
11/02/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TYME
Fax
N/A
Employees
17
Year Founded
N/A

Profitability

Net Income
$-23,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.47 per share

Miscellaneous

Free Float
143,104,000
Market Cap
$53.50 million
Optionable
Optionable
Beta
0.93
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:TYME) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners